ORIGINAL RESEARCH PAPER

Oral & Maxillofacial Pathology

REVERSING DIABETES: STEM CELL ISLETS, SYNERGISTIC DRUG COCKTAILS, AND THE END OF INSULIN DEPENDENCE

KEY WORDS:

Arif Mohiddin B.D.S , M.D.S.Assistant Professor Oral and Maxillofacial Pathology North Bengal Dental College & Hospital

ABSTRACT

Diabetes mellitus is defined by the loss of functional pancreatic beta cell mass. This mini-review highlights the major 2025–2026 advances: (1) DYRK1A inhibitors + GLP-1 agonists achieve 5–8% human beta cell proliferation through synergistic cAMP/PKA and NFAT signaling; (2) Zimislecel (VX-880) stem cell–derived islets produced insulin independence in 83% of T1D patients at 12 months; (3) New kinase targets (SIK, TBK1, GPR3) and senescence pathways (IGFBP3/TMEM219) expand the druggable landscape; and (4) The VX-264 encapsulation trial discontinuation underscores that immunoprotection without immunosuppression remains the central engineering challenge.

1. The Core Problem: Beta Cell Loss

Both T1D and T2D converge on islet beta cell failure. In T1D, autoimmune destruction by CD8+ T cells eliminates beta cells. In T2D, glucotoxicity, lipotoxicity, ER stress, and oxidative stress drive beta cell dysfunction and dedifferentiation [1,2].



Figure 1 — Pathological mechanisms destroying beta cells in T1D and T2D.

Key point: Any regenerative therapy must address the specific insult—autoimmunity in T1D, metabolic stress in T2D—while expanding beta cell number.

2. Molecular Regeneration Targets

2.1 DYRK1A Inhibitors + GLP-1 Synergy

DYRK1A inhibition promotes NFAT nuclear translocation, activating cell cycle genes. Alone, DYRK1A inhibitors (harmine, GNF4877, 5-IT) achieve 1–3% human beta cell labeling. The breakthrough: combining any DYRK1A inhibitor with GLP-1 receptor agonists (exenatide, semaglutide, tirzepatide) pushes proliferation to 5–8% through cAMP/PKA/EPAC2 synergy [3,4].

In vivo, harmine + exenatide normalized glucose in human islet–transplanted mice, while single agents failed [3].



Figure 2 — Mechanism of combined DYRK1A and TGFβ inhibition driving adult human beta cell proliferation.

2.2 New Kinase Targets (Beyond DYRK1A)

Unbiased screens identified entirely new proliferation regulators:

- SIK inhibitors — activate unfolded protein response (UPR)–mediated replication [5]
- TBK1 inhibitors — enhance rodent and human beta cell regeneration [5]
- GPR3 — negative regulator of replication via SIK2 modulation; GPR3 antagonism promotes proliferation [5]
- NKX6.1 activators — selectively drive beta cell (not alpha cell) replication via a VGF-dependent pathway [5]

2.3 SGLT2 Inhibitors & Metabolic Reprogramming

SGLT2 inhibitors (empagliflozin, dapagliflozin) protect beta cells from glucotoxicity and, remarkably, facilitate alpha-to-beta transdifferentiation in human islet grafts through indirect metabolic improvement [6,7].



Figure 3 — Metabolic adaptations and reprogramming in islet beta cells under physiological and stress conditions.

3. Cellular Plasticity: Alpha → Beta

Alpha cells retain developmental plasticity. Viral delivery of Pdx1 + MafA converts alpha cells into functional insulin-producing beta-like cells [8]. SGLT2 inhibitors may drive this process physiologically without genetic manipulation [6].



Figure 4 — Alpha-to-beta cell reprogramming via intraductal AAV delivery of Pdx1 and MafA restores beta cell mass.



Figure 5 — Endocrine lineage plasticity: transcription factor networks governing alpha, beta, and delta cell identity.

4. Stem Cell–Derived Islets: The Clinical Leap

4.1 Zimislecel (VX-880)

Vertex's fully differentiated hPSC-derived islet cell therapy achieved landmark results in the FORWARD-101 Phase 1/2 trial (data presented June 2025) [9,10]:

Table :-1

Outcome	Result (n=12, 12 months)
C-peptide production	100% durable, glucose-responsive
HbA1c <7% + Time-in-range >70%	100%
Severe hypoglycemia	0 events from Day 90
Insulin independence	**83% (10/12)**
Daily insulin reduction	92% mean

Zimislecel has received FDA RMAT/Fast Track and EMA PRIME designations. Phase 3 is underway with regulatory filings expected in 2026 [9,10].

4.2 Encapsulation: The VX-264 Setback

VX-264 used the same cell product inside an immunoprotective device to avoid immunosuppression. The trial was discontinued in March 2025 because C-peptide increases were insufficient to deliver clinical benefit, likely due to inadequate vascularization and/or immune protection [11,12].



Figure 6 — Clinical metabolic outcomes from encapsulated stem cell–derived beta cells in early T1D patients (pre-VX-264 discontinuation data).

4.3 Next-Generation Approaches

- Hypoimmunogenic cells: CRISPR knockout of HLA + PD-L1/CD47 overexpression to evade immune recognition [13]
- Autologous CiPSC-islets: First-in-human abdominal transplantation in T2D showed glucose-responsive insulin secretion without tumors over 116 weeks [13,14]
- RGB-5088: China's first approved autologous stem cell–derived islet trial product (NMPA, Dec 2024) [14]



Figure 7 — Fluorescence microscopy of stem cell–derived beta-like cells (red = insulin; green = C-peptide; blue = nuclei).

5. Combination Therapy Roadmap

The future is multi-modal:

Table :-2

Strategy	Components	Rationale
Proliferation	DYRK1A inhibitor + GLP-1 RA	Synergistic mitogenic signaling [3]
Survival	GLP-1 RA + SGLT2i	Anti-apoptotic + anti-glucotoxic [6,7]
Identity	Metformin + Semaglutide	Prevents dedifferentiation [15]
Immunity	Anti-IL-21 + Liraglutide	Immune modulation + beta cell preservation [1]
Senescence	IGFBP3/TMEM219 blockade	Clears senescent beta cells, enables replication [5]

6. CONCLUSION

Beta cell regeneration has transitioned from bench concept to bedside reality. The harmine + GLP-1 synergy model proves that rational combinations can convert weak mitogens into potent regenerative stimuli. Zimislecel has proven that stem cell–derived islets can restore endogenous insulin production and independence. Yet the VX-264 failure reminds us that immunoprotection without drugs remains unsolved. The next 2–3 years will determine whether pharmacological regeneration, cell replacement, or their combination becomes the standard of care for diabetes.

REFERENCES

[1] Parsi P, et al. Drug-induced regeneration of pancreatic beta cells: An approach to cellular therapeutic targets. Cell Regeneration. 2025;14:39.
[2] Chen S, et al. The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2025.
[3] Wang P, et al. GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration. Sci Transl Med. 2023;15(684):eabq4160.
[4] Ackeifi C, et al. Harnessing beta-cell replication: advancing molecular insights to regenerative therapies in diabetes. Front Endocrinol. 2025;16:1612576.
[5] Ackeifi C, et al. (2025) — Novel targets including SIK, TBK1, GPR3, and IGFBP3/TMEM219 senescence axis. Front Endocrinol. 2025;16:1612576.
[6] Parsi P, et al. (2025) — SGLT2 inhibitors and alpha-to-beta transdifferentiation. Cell Regeneration. 2025;14:39.
[7] Shirakawa J, et al. Alpha-to-beta cell trans-differentiation for treatment of diabetes. J Clin Invest. 2022.
[8] Shirakawa J, et al. (2022) — Viral Pdx1/MafA reprogramming. J Clin Invest. 2022.
[9] Vertex Pharmaceuticals. Positive Data for Zimislecel in Type 1 Diabetes at ADA 85th Scientific Sessions. June 2025. NEJM simultaneous publication.
[10] Vertex Pharmaceuticals. Program Updates for Type 1 Diabetes Portfolio. March 2025.
[11] Type1Strong. Vertex's VX-264 Clinical Trial Fails to Produce Results & Ends Abruptly. April 2025.
[12] JDCA. Critical Update: Vertex's T1D Cure Trial Ends, Research Continues. April 2025.
[13] Anazodo K, et al. Advances in stem cell–derived beta-cell therapy. Nat Rev Endocrinol. 2025.
[14] Shirakawa J, et al. Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles. Cells. 2026;15(2):191.
[15] Kuloğlu M, et al. Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on -Cell Maintenance. Int J Mol Sci. 2025;26(1):421.